Cargando…
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to imm...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137275/ https://www.ncbi.nlm.nih.gov/pubmed/34035548 http://dx.doi.org/10.1055/a-1464-1221 |
_version_ | 1783695588092542976 |
---|---|
author | Ditsch, Nina Stickeler, Elmar Behrens, Annika Belleville, Erik Fasching, Peter A. Fehm, Tanja N. Hartkopf, Andreas D. Jackisch, Christian Janni, Wolfgang Kolberg-Liedtke, Cornelia Kolberg, Hans-Christian Lüftner, Diana Lux, Michael P. Müller, Volkmar Schneeweiss, Andreas Schütz, Florian Schulmeyer, Carla E. Tesch, Hans Thomssen, Christoph Uleer, Christoph Untch, Michael Welslau, Manfred Wöckel, Achim Wurmthaler, Lena A. Würstlein, Rachel Thill, Marc Aktas, Bahriye |
author_facet | Ditsch, Nina Stickeler, Elmar Behrens, Annika Belleville, Erik Fasching, Peter A. Fehm, Tanja N. Hartkopf, Andreas D. Jackisch, Christian Janni, Wolfgang Kolberg-Liedtke, Cornelia Kolberg, Hans-Christian Lüftner, Diana Lux, Michael P. Müller, Volkmar Schneeweiss, Andreas Schütz, Florian Schulmeyer, Carla E. Tesch, Hans Thomssen, Christoph Uleer, Christoph Untch, Michael Welslau, Manfred Wöckel, Achim Wurmthaler, Lena A. Würstlein, Rachel Thill, Marc Aktas, Bahriye |
author_sort | Ditsch, Nina |
collection | PubMed |
description | This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights. |
format | Online Article Text |
id | pubmed-8137275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-81372752021-05-24 Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers Ditsch, Nina Stickeler, Elmar Behrens, Annika Belleville, Erik Fasching, Peter A. Fehm, Tanja N. Hartkopf, Andreas D. Jackisch, Christian Janni, Wolfgang Kolberg-Liedtke, Cornelia Kolberg, Hans-Christian Lüftner, Diana Lux, Michael P. Müller, Volkmar Schneeweiss, Andreas Schütz, Florian Schulmeyer, Carla E. Tesch, Hans Thomssen, Christoph Uleer, Christoph Untch, Michael Welslau, Manfred Wöckel, Achim Wurmthaler, Lena A. Würstlein, Rachel Thill, Marc Aktas, Bahriye Geburtshilfe Frauenheilkd This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights. Georg Thieme Verlag KG 2021-05 2021-05-03 /pmc/articles/PMC8137275/ /pubmed/34035548 http://dx.doi.org/10.1055/a-1464-1221 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Ditsch, Nina Stickeler, Elmar Behrens, Annika Belleville, Erik Fasching, Peter A. Fehm, Tanja N. Hartkopf, Andreas D. Jackisch, Christian Janni, Wolfgang Kolberg-Liedtke, Cornelia Kolberg, Hans-Christian Lüftner, Diana Lux, Michael P. Müller, Volkmar Schneeweiss, Andreas Schütz, Florian Schulmeyer, Carla E. Tesch, Hans Thomssen, Christoph Uleer, Christoph Untch, Michael Welslau, Manfred Wöckel, Achim Wurmthaler, Lena A. Würstlein, Rachel Thill, Marc Aktas, Bahriye Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title | Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title_full | Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title_fullStr | Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title_full_unstemmed | Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title_short | Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers |
title_sort | update breast cancer 2021 part 2 – advanced stages, long-term consequences and biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137275/ https://www.ncbi.nlm.nih.gov/pubmed/34035548 http://dx.doi.org/10.1055/a-1464-1221 |
work_keys_str_mv | AT ditschnina updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT stickelerelmar updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT behrensannika updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT bellevilleerik updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT faschingpetera updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT fehmtanjan updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT hartkopfandreasd updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT jackischchristian updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT janniwolfgang updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT kolbergliedtkecornelia updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT kolberghanschristian updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT luftnerdiana updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT luxmichaelp updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT mullervolkmar updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT schneeweissandreas updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT schutzflorian updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT schulmeyercarlae updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT teschhans updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT thomssenchristoph updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT uleerchristoph updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT untchmichael updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT welslaumanfred updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT wockelachim updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT wurmthalerlenaa updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT wurstleinrachel updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT thillmarc updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers AT aktasbahriye updatebreastcancer2021part2advancedstageslongtermconsequencesandbiomarkers |